Moleculin Biotech is seeking SEC registration with ROTH Capital Partners acting as financial advisor.
3 reports, 1 independent
Updated Jun 30
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Moleculin Biotech is seeking SEC registration with ROTH Capital Partners acting as financial advisor.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Moleculin Biotech is seeking SEC registration with ROTH Capital Partners.1 source
Roth outlines expansion plan and secures development agreements with Ryan, LLC.1 source
Keep exploring
The entities involved
-
ROTH Capital Partners
American small privately held investment banking company
Nothing else this week.
-
Securities and Exchange Commission (Bangladesh)
government regulatory body overseeing the stock market
Related events
- Evolution Petroleum Corporation, Inc. filed an offering with the SEC, with ROTH Capital Partners serving as the sole book-running manager. The bookrunner's office is located in Newport Beach.
- ROTH Capital Partners is discussing access to U.S. capital markets, with Robert Stephenson as the Managing Director.
Coverage
Newest first; wire copies grouped- GlobeNewswireMoleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stag
- GlobeNewswire24/7 Market News: It’s Only Rock and Roll, but I Like It - VENU Raises $30M VENU Secures $30 Million Institutional Investment at $12/Share — Expands Pipeline to $2 Billion Ticket Sales Potential DENV